Le Lézard
Classified in: Health
Subjects: HEALTH, MISCELLANEOUS

Health Coalition Exposes Significantly Higher Costs & Irregularities in Kingston Hospital Cataract Surgery Privatization: New Report


KINGSTON, Ontario, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The KHC's new report, A Clear-Eyed Analysis of Cataract Surgery Privatization, examined two years, November 24, 2021, to September 30, 2023, of Kingston Health Sciences Centre (KHSC) privatizing cataract surgeries to a private for-profit chain, Focus Medical Ancillary (FMA). The cost to the health care system was $2,036,779, a 56% increase over what it would have cost to perform the same services in the public hospital.

The data was compiled from documents released after Freedom of Information requests. "The private cataract surgery contract means $2 million is lost to the public health system. Instead, these funds were used to build up a more expensive for-profit health care provider," commented Ross Sutherland, KHC co-chair and author of the report. "On top of the increased cost, the $2 million spent supporting a more expensive private facility is ultimately outside the control of the hospital or government. It is subject to the workings of the market. The company could go bankrupt or move on, either way taking the benefit of that public investment."

"The 56% increase in cost over doing the surgeries in the public hospital is public money that could have been spent opening unused hospital operating rooms, retaining and expanding staff, or funding cataract surgeries in a smaller, nearby, regional hospital, such as in Napanee."

The Coalition also found that the KHSC-FMA contract lacks transparency, an ongoing problem with public money being spent on for-profit corporations. The private corporate partner is not clear. Proper extensions in the contract are in doubt. Is it a temporary "occupancy agreement", or a more in-depth long-term privatization? And, what options, like opening closed hospital operating rooms, were considered?

Possible conflicts of interests in the creation of the privatization contract were identified and the approval of the contract appears to violate the procurement directives under the Public Sector Accountability Act.

"Without transparency there cannot be public accountability and trust that decisions are being made in the public's interest not for private for-profit interests," argued Joan Jardin, the other KHC Co-Chair. "To begin to establish trust in the system, and stop the waste of public money, the private cataract surgery contract needs to be ended as soon as possible."

The full report can be found at: https://www.ontariohealthcoalition.ca/index.php/release-report-health-coalition-exposes-significantly-higher-costs-irregularities-in-kingston-hospital-cataract-surgery-privatization-new-report/

For more information: Ross Sutherland, Kingston Health Coalition co-chair (613) 532-7846 or Joan Jardin Kingston Health Coalition co-chair (613) 305-2716.



These press releases may also interest you

at 02:05
Locate Bio, a pioneering orthobiologics company, today announces the successful completion of an oversubscribed £9.2 million funding round from both new investors and existing investors, Mercia Ventures and BGF. The proceeds will fund a clinical...

at 02:05
Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...

at 01:00
April 29, 2024 First-quarter highlights Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4%Comparable order intake -3.8%, mainly due to ChinaUSD 1.1 billion Respironics litigation settlement reached in the US...

at 00:45
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of ?15 million in its second closing with participation from...

at 00:20
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx. PPI...

at 00:00
Building on its commitment to identify strengths and gaps in the R&D pipeline for antivirals, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead...



News published on and distributed by: